Form 4: Braden Michael Leonard Increases Stake in Aclaris Therapeutics

Director Braden Michael Leonard reports purchasing additional shares of Aclaris Therapeutics, Inc. (ACRS) through BML Investment Partners, L.P.

Summary

• On July 30, 2024, Braden Michael Leonard, a director of Aclaris Therapeutics, Inc., indirectly acquired 173,730 shares of ACRS common stock at a weighted average price of $1.303 per share.
• On July 31, 2024, Leonard indirectly acquired another 100,000 shares at a weighted average price of $1.3264 per share.
• These purchases were made through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner, and Leonard is the managing member.
• Following these transactions, Leonard's indirect beneficial ownership in ACRS totals 13,876,421 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed as a positive sign, but the document is simply reporting the facts of the transaction.

Positives

• The director's purchase of additional shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track confidence levels and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates